425 related articles for article (PubMed ID: 32358890)
1. Cutaneous sıde-effects of the potential COVID-19 drugs.
Türsen Ü; Türsen B; Lotti T
Dermatol Ther; 2020 Jul; 33(4):e13476. PubMed ID: 32358890
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
3. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
Shah M; Sachdeva M; Dodiuk-Gad RP
Dermatol Ther; 2020 Jul; 33(4):e13524. PubMed ID: 32383251
[No Abstract] [Full Text] [Related]
4. Race to find COVID-19 treatments accelerates.
Kupferschmidt K; Cohen J
Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
6. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
[TBL] [Abstract][Full Text] [Related]
7. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Marto N; Monteiro EC
Acta Med Port; 2020 Jul; 33(7-8):500-504. PubMed ID: 32425152
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.
Li L; Wang X; Wang R; Hu Y; Jiang S; Lu X
Drug Des Devel Ther; 2020; 14():3001-3013. PubMed ID: 32801640
[TBL] [Abstract][Full Text] [Related]
9. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine and hydroxychloroquine in covid-19.
Ferner RE; Aronson JK
BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
[No Abstract] [Full Text] [Related]
12. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
13. Antiviral treatment of COVID-19.
Şimşek Yavuz S; Ünal S
Turk J Med Sci; 2020 Apr; 50(SI-1):611-619. PubMed ID: 32293834
[TBL] [Abstract][Full Text] [Related]
14. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.
Martinez-Lopez A; Cuenca-Barrales C; Montero-Vilchez T; Molina-Leyva A; Arias-Santiago S
J Am Acad Dermatol; 2020 Dec; 83(6):1738-1748. PubMed ID: 32777318
[TBL] [Abstract][Full Text] [Related]
15. Interactions of recommended COVID-19 drugs with commonly used psychotropics.
Chatterjee SS; Malathesh BC; Das S; Singh OP
Asian J Psychiatr; 2020 Aug; 52():102173. PubMed ID: 32446195
[No Abstract] [Full Text] [Related]
16. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
Guastalegname M; Vallone A
Clin Infect Dis; 2020 Jul; 71(15):888-889. PubMed ID: 32211771
[No Abstract] [Full Text] [Related]
17. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
18. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798
[No Abstract] [Full Text] [Related]
19. [Potential therapeutic drugs for novel coronavirus pneumonia].
Nie NF; He Y
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Nov; 43(11):970-974. PubMed ID: 33137863
[TBL] [Abstract][Full Text] [Related]
20. Antiviral therapy for coronavirus disease 2019.
Gong S; Su J; Yan X; Li F; Hu L; Liu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
